A critical review of pyritinol
- 6 Downloads
Pyritinol (pyrithioxine) is a combination of two molecules of vitamin B6 (pyridoxine) with disulfide linkage. Its pharmacokinetic profile mimics that of its parent compound. Because it crosses the blood–brain barrier, its major clinical utility is in brain-related disorders. Pyritinol regulates signalling pathways of various neurotransmitters including acetylcholine, γ-aminobutyric acid, N-methyl-d-aspartate, etc. Pyritinol has also been shown to act as an antioxidant and anti-inflammatory agent, and also reduces plasma viscosity. It is indicated in paediatric populations to treat learning disabilities, developmental dysphasia, postnatal hypoxia and other cognitive disorders. In adults, it is indicated for improving cognition and memory, Alzheimer’s disease, multi-infarct dementia and rheumatoid arthritis. It has also been investigated in many other clinical conditions, but results are inconclusive. The positive results of many animal studies have not been replicated into consistent clinical success. This review aims to discuss potential uses of pyritinol and its future prospects.
Compliance with ethical standards
Conflict of interest
Authors declare no conflicts of interest relevant to this article.
No funding received from any source.
- 6.Turský T. Pyritinol inhibition of the GABA and benzodiazepine receptor. Physiol Bohemoslov. 1988;37(5):417–26.Google Scholar
- 7.Seth SD, Seth V, editors. Textbook of pharmacology. 3rd ed. New Delhi: Elsevier; 2009.Google Scholar
- 9.Jaiswal AK, Upadhyay SN, Bhattacharya SK. Effect of pyritinol, a cerebral protector, on learning and memory deficits induced by prenatal undernutrition and environmental impoverishment in young rats. Indian J Exp Biol. 1990;28(7):609–15.Google Scholar
- 11.Dayrens P, Ivanoff B, Cussac M, et al. Antiinflammatory and immunostimulant activities of six sulphur compounds—four benzenesulphonates, levamisole, and pyritinol hydrochloride—assayed in mouse cell activation studies. Arzneimittelforschung. 1983;33(3):372–7.Google Scholar
- 13.Zavadenko NN, Kozlova EV, Koltunov IE. Developmental dysphasia: assessment of the drug treatment efficacy (in Russian). Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(7 Pt 2):90–5.Google Scholar
- 14.Zavadenko NN, Kozlova EV. Nootropic drug therapy for developmental dysphasia in children (in Russian). Voprosy Prakticheskoi Pediatrii. 2013;8(5):24–8.Google Scholar
- 15.Nair MK, George B, Jeyaseelan L. Pyritinol for post asphyxial encephalopathy in term babies: a randomized double-blind controlled trial. Indian Pediatr. 2009;46(Suppl):s37–42.Google Scholar
- 16.Zykov VP, Begasheva OI. Cognitive disturbances in patients with tics and Tourette’s syndrome and their correction with encephabol (in Russian). Zh Nevrol Psikhiatr Im S S Korsakova. 2003;103(11):10–4.Google Scholar
- 17.Zenkov LR, Zenkova AL. Encephabol in the treatment of cognitive disorders in epilepsy (in Russian). Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(5 Pt 2):77–80.Google Scholar
- 18.Hindmarch I, Coleston DM, Kerr JS. Psychopharmacological effects of pyritinol in normal volunteers. Neuropsychobiology. 1990–1991;24(3):159–64.Google Scholar
- 25.Khan MA, Jensen K, Krogh HJ. Alcohol-induced hangover: a double-blind comparison of pyritinol and placebo in preventing hangover symptoms. Q J Stud Alcohol. 1973;34(4):1195–201.Google Scholar
- 26.Shah A, St. Clair EW. Rheumatoid arthritis. Harrison’s principles of internal medicine. 20th ed. New York: McGraw-Hill Education; 2018.Google Scholar